Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1901-1920 of 3,900 trials

AMG 193 for Advanced Thoracic Tumors

We are studying the effects of AMG 193, alone and with other treatments, in patients with advanced thoracic tumors that have a specific genetic deletion. This research aims to find better treatment options for these patients.

Non-small Cell Lung CancerThoracic Tumors with Homozygous MTAP-deletionSafety phase (I)Oncology

Atopic Dermatitis: APG777 Treatment Study

We are studying a new treatment called APG777 for people with moderate-to-severe atopic dermatitis. The goal is to see if it helps reduce symptoms like itching and skin pain compared to a placebo.

Atopic Dermatitis>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Glioblastoma: Meclofenamate with Temozolomide

We are studying whether adding meclofenamate to standard temozolomide therapy helps patients with progressive MGMT-methylated glioblastoma. The trial will assess safety, effectiveness, and quality of life improvements.

Glioblastoma>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Colorectal Polyp Removal: Anticoagulants and Antiplatelets Study

We are investigating whether continuing blood-thinning medications during polypectomy for small colorectal polyps affects bleeding risks. This study will also assess heart-related risks when these medications are stopped.

Healthy Participants Undergoing Colonoscopy>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesGastroenterologyHematology

Blood Cancer: Long-term Study of Zanubrutinib

We are evaluating the long-term safety and effectiveness of Zanubrutinib in patients with B-cell malignancies. This study is for those who have previously participated in a related trial.

B-cell Lymphoma>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology

Non-Small Cell Lung Cancer: Sotorasib Treatment Study

We are studying the effects of Sotorasib in patients with non-operable non-small cell lung cancer who have a KRAS mutation. The goal is to see if this treatment improves survival and response rates compared to standard options.

Stage III Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Refractory Invasive Pulmonary Aspergillosis: Nebulized PC945

We are studying a new nebulized treatment, PC945, for patients with a tough-to-treat fungal infection. The goal is to see if it works better when combined with standard antifungal therapies.

Pulmonary Aspergillosis3-6 monthsConfirmation phase (III)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteInfectious DiseasesPulmonology

Cholestatic Pruritus: Maralixibat Study

We are testing a new medication, maralixibat, for individuals with cholestatic pruritus to see if it can reduce itching and lower bile acid levels in the blood.

Cholestatic PruritusConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesPartially RemoteDermatologyHepatology

Anti-CD19 CAR T-Cell Therapy for Autoimmune Diseases

We are studying a new treatment for people with active B-driven autoimmune diseases like lupus and scleroderma. The trial aims to evaluate its safety and initial effectiveness in managing these conditions.

Refractory Systemic Autoimmune Diseases3-6 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesInfectious DiseasesRheumatology

Myelofibrosis: Selinexor Treatment Study

We are studying the effects of selinexor in patients with myelofibrosis who haven't been treated with JAK inhibitors. The goal is to see if it helps improve symptoms and overall health.

MyelofibrosisModerate ThrombocytopeniaEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementHematology

Amyotrophic Lateral Sclerosis: ARGX-119 Study

We are testing a new treatment called ARGX-119 for adults with ALS to see if it is safe and how well it works in slowing disease progression.

Amyotrophic Lateral Sclerosis (ALS)>2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Advanced Non-Small Cell Lung Cancer: BAY 2927088 Study

We are investigating how well BAY 2927088 works and its safety compared to standard treatment for patients with advanced non-small cell lung cancer with HER2 mutations.

Advanced Non-Small Cell Lung Cancer with HER2 MutationConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Acute Pulmonary Embolism: Reduced Dose Thrombolytic Treatment

We are studying whether a lower dose of thrombolytic therapy is effective and safe for patients with intermediate high-risk acute pulmonary embolism. This research aims to improve treatment outcomes and reduce health risks.

Pulmonary Embolism>2 yearsConfirmation phase (III)≤5 visitsInvestigational MedicinesCardiologyInternal MedicinePulmonology

Tafasitamab for Pediatric Acute B Lineage Leukemia

We are studying a new treatment for children with relapsed or refractory acute B lineage leukemia to see if it can help delay disease relapse and improve survival rates.

Acute Lymphoblastic Leukemia>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesHematologyPediatrics

Oral Propranolol for Preventing Eye Issues in Premature Infants

We are studying whether oral propranolol can help extremely preterm infants lower their risk of developing threshold retinopathy of prematurity. This research aims to improve safety and reduce the need for additional treatments.

Retinopathy of Prematurity>2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesPartially RemoteOphthalmologyPediatrics

Hearing Loss in Children: DB-OTO Gene Therapy

We are testing a new gene therapy for children and infants with hearing loss due to specific genetic mutations. The study aims to see if it is safe and effective in improving their hearing and speech skills.

Congenital Hearing Loss1-2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesOtolaryngologyPediatrics

Acute Myeloid Leukemia: New Oral Drug for IDH1 Mutation

We are testing a new oral medication for patients with AML or other blood cancers that have an IDH1 mutation. The study aims to evaluate the safety and activity of this investigational drug.

Acute Myeloid Leukaemia>2 yearsSafety phase (I)HematologyOncology

Immunological Diseases: RAY121 Treatment

We are testing RAY121 for people with various immunological diseases to see if it can help manage their condition by inhibiting the immune response.

Bullous PemphigoidImmune-Mediated Necrotizing MyopathyDermatomyositis1-2 yearsSafety phase (I)DermatologyRheumatology

Cobolimab and Dostarlimab for Pediatric Tumors

We are studying a combination of two medications for children and young adults with newly diagnosed or relapsed solid tumors. The goal is to evaluate safety and how well it may work against specific cancers.

Hepatic CancerRhabdomyosarcomaGlioma>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncologyPediatrics

Crohn's Disease: EXL01 for Post-Surgery Recurrence Prevention

We are studying whether EXL01 can help prevent the return of Crohn's disease in patients after surgery. This trial compares its effects to a placebo to assess safety and effectiveness.

Crohn's Disease3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesPartially RemoteGastroenterologyInternal Medicine